Lazard Asset Management
TCRT icon

Lazard Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Lazard Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-261
Closed -$19K – 2468
2023
Q2 		$19K Buy
261
+7
+3% +$566 ﹤0.01% 2108
2023
Q1 		$23K Buy
254
+169
+199% +$16.1K ﹤0.01% 2030
2022
Q4 		$8K Buy
+85
New +$12.3K ﹤0.01% 2222

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Lazard Asset Management's TCRT Position: Q3 2023 in Review

Lazard Asset Management sold out of Alaunos Therapeutics (TCRT) in Q3 2023, closing a stake of 261 shares — an estimated $19K sold.

Lazard Asset Management first reported a position in TCRT in Q4 2022 and held it in 3 quarters. The position peaked at $23K in Q1 2023. 89 funds tracked by Wall St. Rank hold TCRT as of Q3 2023.

  • Lazard Asset Management reported no remaining Alaunos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lazard Asset Management sold 261 Alaunos Therapeutics shares in Q3 2023, an estimated $19K.
  • Lazard Asset Management first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 3 quarters.
  • Lazard Asset Management's Alaunos Therapeutics position peaked at $23K in Q1 2023.
  • 89 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2023.

Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.